Cited by 19Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 255 of the 256 references it cites were found in a registry or an index.

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Costa, Bruno Almeida, Mouhieddine, Tarek H., Ortiz, Ricardo J., Richter, Joshua·2023·Critical Reviews in Oncology/Hematology

DOI 10.1016/j.critrevonc.2023.104040

Open this paper in CoChat — free account

Abstract

From the 1960s to the early 2000s, alkylating agents (e.g., melphalan, cyclophosphamide, and bendamustine) remained a key component of standard therapy for newly-diagnosed or relapsed/refractory multiple myeloma (MM). Later on, their associated toxicities (including second primary malignancies) and the unprecedented efficacy of novel therapies have led clinicians to increasingly consider alkylator-free approaches. Meanwhile, new alkylating agents (e.g., melflufen) and new applications of old alkylators (e.g., lymphodepletion before chimeric antigen receptor T-cell [CAR-T] therapy) have emerged in recent years. Given the expanding use of antigen-directed modalities (e.g., monoclonal antibodies, bispecific antibodies, and CAR-T therapy), this review explores the current and future role of alkylating agents in different treatment settings (e.g., induction, consolidation, stem cell mobilization, pre-transplant conditioning, salvage, bridging, and lymphodepleting chemotherapy) to ellucidate the role of alkylator-based regimens in modern-day MM management.

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2023.104040

Cites

255 of 255 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Multiple myeloma
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,261
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,058
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 1,004
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 864
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 802
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 748
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S., Szubert, A. J., Navarro-Coy, N. C., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 580
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 567
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., Palva, I. P., Oivanen, T., Corrado, C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 547
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
McElwain, T. J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 508
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204925 · Cited by 487
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Clinical Pharmacokinetics of Cyclophosphamide
de Jonge, M. E., Huitema, A. D. R., Rodenhuis, S., & Beijnen, J. H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00003 · Cited by 447
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Giralt, S., Costa, L. J., Schriber, J. R., DiPersio, J. F., Maziarz, R. T., McCarty, J. M., Shaughnessy, P. J., Snyder, E. L., Bensinger, W., Copelan, E. A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.013 · Cited by 417
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Treatment for Multiple Myeloma
Alexanian, R. (1969) · JAMA · doi:10.1001/jama.1969.03160090040009 · Cited by 395
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Ramos, C. A., Grover, N. S., Beaven, A., Lulla, P., Wu, M.-F., Ivanova, A., Wang, T., Shea, T. C., Rooney, C. M., Dittus, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01342 · Cited by 389
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Cavo, M., Gay, F., Beksaç, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 386
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Mateos, M., Hernández, J., Hernández, M.-T., Gutierrez, N. C., Palomera, L., Fuertes, M., Diaz‐Mediavilla, J., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 384
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Hulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 379
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C. L., Trudel, S., Hentz, J. G., Noble, B. N., Pirooz, N. A., Spong, J., Píza, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 378
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
Leoni, L. M., Bailey, B., Reifert, J. R., Bendall, H. H., Zeller, R. W., Corbeil, J., Elliott, G. T., & Niemeyer, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1061 · Cited by 369
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A. P., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 357
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
Kintzel, P. E. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 354
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K. A., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 336
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Barlogie, B., Anaissie, E. J., van Rhee, F., Haessler, J., Hollmig, K. A., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y. M., Tricot, G. J. K., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 330
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 324
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
Palumbo, A. P., Falco, P., Corradini, P., Falcone, A. P., Raimondo, F. D., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 317
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
Duell, J., Dittrich, M. T., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 279
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Bréchignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 271
Bendamustine: Rebirth of an Old Drug
Cheson, B. D., & Rummel, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7252 · Cited by 266
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Miguel, J. F. S., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., Samoilova, O. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 263
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00685 · Cited by 259
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Wijermans, P., Schaafsma, M. R., Termorshuizen, F., Ammerlaan, R., Wittebol, S. H., Sinnige, H. A. M., Zweegman, S., Kooy, M. V. M., van der Griend, R., Lokhorst, H. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 259
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Gay, F., Musto, P., Rota-Scalabrini, D., Bertamini, L., Belotti, A., Galli, M., Offidani, M., Zamagni, E., Ledda, A., Grasso, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00535-0 · Cited by 258
Current status of autologous stem cell transplantation for multiple myeloma
Hamed, R. A., Bazarbachi, A. H., Malard, F., Harousseau, J., & Mohty, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0205-9 · Cited by 256
Multiple myeloma treated with high dose intravenous melphalan
Selby, P. J., McElwain, T. J., Nandi, A., Perren, T. J., Powles, R., Tillyer, C. R., Osborne, R. J., Slevin, M. L., & Malpas, J. S. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.tb06890.x · Cited by 248
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 242
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol
Case, D. C., Lee, B. J., & Clarkson, B. D. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90543-5 · Cited by 218
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Palumbo, A. P., Bringhen, S., Larocca, A., Rossi, D., Raimondo, F. D., Magarotto, V., Patriarca, F. F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 207
Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
Pönisch, W., Mitrou, P. S., Merkle, K., Herold, M. J., Aßmann, M., Wilhelm, G., Dachselt, K., Richter, P., Schirmer, V., Schulze, A., et al. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0074-4 · Cited by 186
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00428-9 · Cited by 184
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Facon, T. T. F. (2005) · Blood · doi:10.1182/blood-2005-04-1588 · Cited by 180
DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma
Lee, C., Barlogie, B., Munshi, N. C., Zangari, M., Fassas, A., Jacobson, J. L., van Rhee, F., Cottler‐Fox, M., Muwalla, F., & Tricot, G. J. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 169
Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma
Kropff, M. H., Bisping, G., Schuck, E., Liebisch, P., Lang, N., Hentrich, M., Dechow, T. N., Kröger, N. M., Salwender, H. J., Metzner, B., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06656.x · Cited by 166
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E. J., Tricot, G. J. K., van Rhee, F., Crowley, J. J., Shaughnessy, J. D., & Barlogie, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06921.x · Cited by 165
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Baz, R., Martin, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 161
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Richardson, P. G. G., Oriol, A., Larocca, A., Bladé, J., Cavo, M., Rodríguez‐Otero, P., Leleu, X. P., Nadeem, O., Hiemenz, J. W., Hassoun, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02259 · Cited by 161
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3211 · Cited by 156
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedè, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 153
p53 and MDM2 alterations in osteosarcomas
Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8 · Cited by 147
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 145
Therapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 144
CLINICAL EXPERIENCES WITH SARCOLYSIN IN NEOPLASTIC DISEASES
Blokhin, N. N., Lf, L., Переводчикова, Н. И., Chebotareva, L., & Merkulova, N. A. (1958) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1958.tb42675.x · Cited by 140
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Pour, L., Jurczyszyn, A. J., Qiu, L., Klippel, Z. K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 129
CAR-T efficacy: is conditioning the key?
Neelapu, S. S. (2019) · Blood · doi:10.1182/blood-2019-03-900928 · Cited by 129
Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).
Bergsagel, D. E., Cc, S., AUSTIN, C., & Griffith, K. M. (1962) · PubMed · Cited by 125
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto, M., Comotti, B., & Dammacco, F. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.444 · Cited by 122
Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Bayraktar, U. D., Bashir, Q., Qazilbash, M. H., Champlin, R. E., & Ciurea, S. O. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.011 · Cited by 121
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M. M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 119
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., Riggs, D. L., Shi, C., Stein, C. K., Bergsagel, M., Chau, B. H., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0038 · Cited by 116
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Zweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 115
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Lahuerta, J. J., Mateos, M. V., Martínez‐López, J., Grande, C., de la Rubia, J., Rosiñol, L., Sureda, A. M., García‐Laraña, J., Díaz-Mediavilla, J., Hernández‐Garcia, M. T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028027 · Cited by 110
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Chauhan, D., Ray, A., Viktorsson, K., Spira, J., Paba‐Prada, C. E., Munshi, N. C., Richardson, P. G. G., Lewensohn, R., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3752 · Cited by 106
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Caraccio, C., Krishna, S., Phillips, D. J., & Schürch, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00501 · Cited by 106
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.521 · Cited by 104
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Mateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Martínez, R., Palomera, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573733 · Cited by 103
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
Morgan, G. J., Schey, S., Wu, P., Srikanth, M., Phekoo, K. J., Jenner, M. W., & Davies, F. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06538.x · Cited by 102
Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
Reece, D. E., Rodriguez, G. P., Chen, C. I., Trudel, S., Kukreti, V., Mikhael, J. R., Pantoja, M. A., Xu, W., & Stewart, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2372 · Cited by 101
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Jayaweera, S. P. E., Kanakanamge, S. P. W., Rajalingam, D., & Silva, G. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740796 · Cited by 101
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100
Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB
Jb, H., Pajak, T., McIntyre, O. R., Kochwa, S., Cooper, M., Coleman, M., & Cuttner, J. (1979) · Blood · doi:10.1182/blood.v54.1.13.13 · Cited by 97
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Palumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., Ria, R., Pisani, F., Cangialosi, C., Caravita, T., et al. (2009) · Blood · doi:10.1182/blood-2009-09-241737 · Cited by 97
The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 95
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
Bashir, Q., Thall, P. F., Milton, D. R., Fox, P. S., Kawedia, J. D., Kebriaei, P., Shah, N. D., Patel, K. K., Andersson, B. S., Nieto, Y. L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30023-7 · Cited by 95
Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Auner, H. W., Iacobelli, S., Sbianchi, G., Knol, C., Blaise, D., Russell, N. H., Apperley, J. F., Pohlreich, D., Browne, P., Kobbe, G., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.181339 · Cited by 95
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 92
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Wickström, M., Nygren, P., Larsson, R. L., Harmenberg, J., Lindberg, J., Sjöberg, P. J. R., Jerling, M., Lehmann, F., Richardson, P. G. G., Anderson, K. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18420 · Cited by 89
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 88
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Durie, B. G. M., Dixon, D. O., Carter, S. K., Stephens, R. L., Rivkin, S. E., Bonnet, J. D., Salmon, S. E., Dabich, L., Files, J. C., & Costanzi, J. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1227 · Cited by 88
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., Galli, M., Marcatti, M., Verde, G. L., Giuliani, N., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488676 · Cited by 85
Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma
Drago, J. R., Santen, R. J., Lipton, A., Worgul, T. J., Harvey, H. A., Boucher, A. E., Manni, A., & Rohner, T. J. (1984) · Cancer · doi:10.1002/1097-0142(19840401)53:7 · Cited by 85
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
Richardson, P. G. G., Bringhen, S., Voorhees, P. M., Plesner, T., Mellqvist, U., Reeves, B., Paba‐Prada, C. E., Zubair, H., Byrne, C., Chauhan, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30044-2 · Cited by 83
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Schjesvold, F. H., Dimopoulos, M. A., Delimpasi, S., Robak, P., Coriu, D., Legiec, W., Pour, L., Špička, I., Masszi, T., Doronin, V., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00381-1 · Cited by 82
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Roué, G., López‐Guerra, M., Milpied, P. J., Pérez‐Galán, P., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0388 · Cited by 82
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
Pönisch, W., Rozanski, M. J., Goldschmidt, H., Hoffmann, F. A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07076.x · Cited by 80
T‐cell modulation by cyclophosphamide for tumour therapy
Hughes, E., Scurr, M. J., Campbell, E., Jones, E., Godkin, A. J., & Gallimore, A. (2018) · Immunology · doi:10.1111/imm.12913 · Cited by 80
Melphalan in Multiple Myeloma
Hoogstraten, B., Sheehe, P. R., Cuttner, J., Cooper, T., Kyle, R. A., Oberfield, R. A., Townsend, S. R., HARLEY, J. B., Hayes, D. M., Costa, G., et al. (1967) · Blood · doi:10.1182/blood.v30.1.74.74 · Cited by 80
Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches
Poczta, A., Rogalska, A., & Marczak, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091841 · Cited by 78
The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)
Davies, F. E., Wu, P., Jenner, M. W., Srikanth, M., Saso, R. M., & Morgan, G. J. (2007) · Haematologica · doi:10.3324/haematol.11228 · Cited by 72
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
Yimer, H. A., Melear, J. M., Faber, E. A., Bensinger, W., Burke, J. M., Narang, M., Stevens, D. A., Gunawardena, S. W., Lutska, Y., Qi, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15806 · Cited by 69
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
Radivoyevitch, T., Dean, R. M., Shaw, B. E., Brazauskas, R., Tecca, H. R., Molenaar, R. J., Battiwalla, M., Savani, B. N., Flowers, M. E. D., Cooke, K. R., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.016 · Cited by 68
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 68
Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG ‐ HD 2 trial
Mai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 67
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0724-1 · Cited by 67
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
Chari, A., Rodríguez‐Otero, P., McCarthy, H. O., Suzuki, K., Hungria, V., Sureda, A. M., Perrot, A., Hulin, C., Magen, H., Iida, S., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16980 · Cited by 66
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre‐Barbe, M., Lafon, I., Facon, T. T. F., Leleu, X. P., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65
Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Lakshman, A., Singh, P. P., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dingli, D., Hwa, Y. L., Fonder, A. L., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24954 · Cited by 64
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 62
Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells
Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 61
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J. B., Laumann, K. M., Greipp, P. R., Lust, J. A., Gertz, M. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22053 · Cited by 61
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Mateos, M., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y. A., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103120 · Cited by 60
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé, J., Miguel, J. F. S., Alcalá, A., Maldonado, J., Sanz, M. Á., García-Conde, J., Moro, M. J., Alonso, C., Besalduch, J., & Zubizarreta, A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1165 · Cited by 59
Long-Term Physiological Side Effects After Allogeneic Bone Marrow Transplantation
Mohty, M., & Apperley, J. F. (2010) · Hematology · doi:10.1182/asheducation-2010.1.229 · Cited by 59
Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma
Tuchman, S. A., Bacon, W., Huang, L., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Chute, J. P., Sullivan, K. M., Engemann, A. M., Yopp, A., et al. (2014) · Journal of Clinical Apheresis · doi:10.1002/jca.21360 · Cited by 59
Bendamustine: a review of pharmacology, clinical use and immunological effects (Review)
Lalić, H., Aurer, I., Batinić, D., Višnjić, D., Smoljo, T., & Babić, A. (2022) · Oncology Reports · doi:10.3892/or.2022.8325 · Cited by 59
How to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 58
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Mateos, M., Martínez‐López, J., Hernández, M.-T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutierrez, N. C., Ramos, M.-L. M., Oriol, A., et al. (2015) · Blood · doi:10.1182/blood-2015-08-666537 · Cited by 57
The mutagenic impact of melphalan in multiple myeloma
Maura, F., Weinhold, N., Diamond, B. T., Kazandjian, D. G., Rasche, L., Morgan, G. J., & Landgren, O. (2021) · Leukemia · doi:10.1038/s41375-021-01293-3 · Cited by 57
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Nijhof, I. S., Franssen, L. E., Levin, M., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 55
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Swan, D., Gurney, M. E., Krawczyk, J., Ryan, A. E., & O'Dwyer, M. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000350 · Cited by 55
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
Miettinen, J. J., Kumari, R., Traustadóttir, G. Á., Huppunen, M.-E., Sergeev, P., Majumder, M. M., Schepsky, A., Guðjónsson, Þ., Lievonen, J., Bazou, D., et al. (2021) · Cancers · doi:10.3390/cancers13071527 · Cited by 55
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016
Hungria, V., Martinez-Banos, D. M., Peñafiel, C. O. R., Miguel, C. E., Vela‐Ojeda, J., Remaggi, G., Duarte, F. B., Cao, C., Cugliari, M. S., SANTOS, T. M. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16124 · Cited by 54
Melphalan hydrochloride for the treatment of multiple myeloma
Esma, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349102 · Cited by 53
Phase I / II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
Berenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel‐Donnelly, D., Siegel, R. S., Kewalramani, T., Gorak, E. J., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12129 · Cited by 52
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 52
Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing ProdrugJ1
Gullbo, J., Wickström, M., Tullberg, M. L., Ehrsson, H., Lewensohn, R., Nygren, P., Luthman, K., & Larsson, R. L. (2003) · Journal of drug targeting · doi:10.1080/10611860310001647140 · Cited by 52
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
Olivier, T., & Prasad, V. K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101374 · Cited by 51
High‐dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment‐related mortality in patients with multiple myeloma: results of a randomised study
Fenk, R. R., Schneider, P., Kropff, M. H., Huenerlituerkoglu, A.-N., Steidl, U. U., Aul, C., Hildebrandt, B., Haas, R. R., Heyll, A., Kobbe, G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05641.x · Cited by 49
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma
Griffin, P. T., Ho, V. Q., Fulp, W. J., Nishihori, T., Shain, K. H., Alsina, M., & Baz, R. (2015) · Cancer · doi:10.1002/cncr.29533 · Cited by 48
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisone
Hjorth, M., Hellquist, L., Holmberg, E. C., Magnusson, B., Rödjer, S., Westin, J., & for the Myeloma Group of Western Sweden (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02564.x · Cited by 48
Second malignancies in multiple myeloma; emerging patterns and future directions
Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 48
Bendamustine in patients with relapsed or refractory multiple myeloma
Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A. G., Safaian, N., Neumann, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-13 · Cited by 47
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Mikhael, J. R., Reeder, C. B., Libby, E. N., Costa, L. J., Bergsagel, P. L., Buadi, F. K., Mayo, A., Reddy, S. K. N., Gano, K., Dueck, A. C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13296 · Cited by 45
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
Costa, L. J., Iacobelli, S., Pasquini, M. C., Modi, R. A., Giaccone, L., Bladé, J., Schönland, S. O., Evangelista, A., Pérez‐Simón, J. A., Hari, P., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0887-4 · Cited by 45
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
Damaj, G. L., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A., Baños, A., Morineau, N., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.622422 · Cited by 44
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
Fenk, R. R., Michael, M., Zohren, F., Graef, T. T., Czibere, A. G., Bruns, I., Neumann, F., Fenk, B., Haas, R. R., & Kobbe, G. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701694194 · Cited by 44
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Party, T. K. M. M. W., Kim, Y., Sohn, S., Lee, J.-H., Yang, D.-H., Moon, J., Ahn, J.-S., Kim, H., & Lee, J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0856-x · Cited by 43
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
Bringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 42
Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
Reeder, C. B., Reece, D. E., Kukreti, V., Mikhael, J. R., Chen, C. I., Trudel, S., Laumann, K. M., Vohra, H. S., Fonseca, R., Bergsagel, P. L., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13004 · Cited by 42
HyperCVAD for VAD-resistant multiple myeloma
Dimopoulos, M. A., Weber, D., Kantarjian, H. M., Delasalle, K. B., & Alexanian, R. (1996) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199606)52:2 · Cited by 42
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 41
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
Lazzarino, M., Corso, A., Barbarano, L., Alessandrino, E. P., Cairoli, R., Pinotti, G., Ucci, G., Uziel, L. D., Rodeghiero, F., Fava, S., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703240 · Cited by 40
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Pönisch, W., Bourgeois, M., Moll, B., Heyn, S., Jaekel, N., Wagner, I., Rohrberg, R., Hurtz, H.-J., Schmalfeld, M., Aßmann, M., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1339-3 · Cited by 37
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
Einsele, H., Engelhardt, M. M., Tapprich, C., Müller, J., Liebisch, P., Langer, C., Kropff, M. H., Muegge, L. O., Jung, W. E., Wolf, H., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14920 · Cited by 36
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.247130 · Cited by 36
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Rodon, P., Hulin, C., Pegourié, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.110890 · Cited by 35
Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
Grey‐Davies, E., Bosworth, J. L., Boyd, K. D., Ebdon, C., Saso, R. M., Chitnavis, D., Mercieca, J., Morgan, G. J., & Davies, F. E. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08887.x · Cited by 35
An overview of the progress in the treatment of multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.870030 · Cited by 33
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Dimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., Nahi, H., Gruber, A., Hansson, M., Gupta, N., Byrne, C., Labotka, R., Teng, Z., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.011 · Cited by 33
A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
Bensinger, W., Becker, P. S., Gooley, T. A., Chauncey, T. R., Maloney, D. G., Gopal, A. K., Green, D. J., Press, O. W., Lill, M., Ifthikharuddin, J. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.211 · Cited by 33
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Bringhen, S., D’Agostino, M., Paoli, L. D., Montefusco, V., Liberati, A. M., Galieni, P., Grammatico, S., Muccio, V. E., Esma, F., Angelis, C. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.327 · Cited by 32
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Berglund, Å., Ullén, A., Lisyanskaya, A. S., Орлов, С. В., Hagberg, H., Tholander, B., Lewensohn, R., Nygren, P., Spira, J., Harmenberg, J., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0299-2 · Cited by 32
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
Martino, M. V., Tripepi, G. L., Messina, G., Vincelli, I. D., Console, G., Recchia, A. G., Gentile, M., Molica, S., & Morabito, F. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.94 · Cited by 32
Allogeneic Stem Cell Transplantation in Multiple Myeloma
Greil, C., Engelhardt, M. M., Finke, J., & Wäsch, R. (2021) · Cancers · doi:10.3390/cancers14010055 · Cited by 32
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 30
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
Blommestein, H. M., van Beurden-Tan, C. H. Y., Franken, M. G., Groot, C. A. U., Sonneveld, P., & Zweegman, S. (2019) · Haematologica · doi:10.3324/haematol.2018.206912 · Cited by 30
Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou, M., Papanicolaou, X., Maltesas, D., Megalakaki, C., Patos, P., Panteli, K. E., Repousis, P., & Mitsouli-Mentzikof, C. (2007) · PubMed · Cited by 30
A historical perspective on milestones in multiple myeloma research
Ribatti, D. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13003 · Cited by 29
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
Pönisch, W., Holzvogt, B., Plötze, M., Andrea, M., Bourgeois, M., Heyn, S., Zehrfeld, T., Hammerschmidt, D., Schwarz, M., Edelmann, T., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1737-9 · Cited by 29
Bendamustine in multiple myeloma
Gentile, M., Vigna, E., Recchia, A. G., Morabito, L., Mendicino, F., Giagnuolo, G., & Morabito, F. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12609 · Cited by 29
Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation
Trieu, Y., Trudel, S., Pond, G. R., Mikhael, J. R., Jaksic, W., Reece, D. E., Chen, C. I., & Stewart, A. K. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1578 · Cited by 29
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Reece, D. E., Song, K., LeBlanc, R., Mezzi, K., Olujohungbe, A., White, D. J., Zaman, F., & Belch, A. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0384 · Cited by 27
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
Srour, S. A., Milton, D. R., Bashir, Q., Nieto, Y. L., Saini, N. Y., Daher, M., Ramdial, J., Im, J. S., Hosing, C. M., Delgado, R., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279179 · Cited by 27
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis
Wang, L., Xiang, H., Yan, Y., Deng, Z., Li, H., Li, X., & Liu, J. (2021) · Annals of Hematology · doi:10.1007/s00277-020-04376-w · Cited by 26
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
Mateos, M., Oriol, A., Rosiñol, L., de Arriba, F., Puig, N., Martín, J., Martínez‐López, J., Echeveste, M. A., Sarrá, J., Ocio, E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124818 · Cited by 25
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Yong, K., Wilson, W., Tute, R. M. D., Camilleri, M., Ramasamy, K., Streetly, M. J., Sive, J. I., Bygrave, C., Benjamin, R., Chapman, M., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00350-7 · Cited by 25
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
Kazmi, S. M. A., Saliba, R. M., Donato, M. L., Wang, M., Hosing, C. M., Qureshi, S. R., Anderlini, P. N., Popat, U., Champlin, R. E., Giralt, S., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.160 · Cited by 25
Perspective: An International Fludarabine shortage: Supply Chain Issues Impacting Transplant and Immune Effector Cell Therapy Delivery.
Maziarz, R., Diaz, A. H., Miklos, D., & Shah, N. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.002 · Cited by 24
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
Roussel, M., Lauwers‐Cancès, V., Macro, M., Leleu, X. P., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M., et al. (2022) · Blood · doi:10.1182/blood.2021014635 · Cited by 24
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
Gomez-Arteaga, A., Mark, T. M., Guarneri, D., Christos, P. J., Gergis, U. S., Greenberg, J., Hsu, J., Mayer, S. A., Niesvizky, R., Pearse, R. N., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0587-0 · Cited by 23
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma
Kumar, S. K., Grząśko, N., Delimpasi, S., Wiktor-Jędrzejczak, W., Grosicki, S., Kyrtsonis, M., Spencer, A. G., Gupta, N., Teng, Z., Byrne, C., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15679 · Cited by 23
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial
Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 22
Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
Gourzonès, C., Bret, C., & Moreaux, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00861 · Cited by 22
Current and Novel Alkylators in Multiple Myeloma
Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 22
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
Kumar, S. K., Krishnan, A. Y., LaPlant, B. R., Laumann, K. M., Roy, V., Zimmerman, T. M., Gertz, M. A., Buadi, F. K., Stockerl-Goldstein, K. E., Birgin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24181 · Cited by 22
Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
Waal, E. G. M. D., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A. W. G., Tromp, Y., Vellenga, E., & Hovenga, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13653 · Cited by 20
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 20
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study
Kropff, M. H., Vogel, M., Bisping, G., Schlag, R., Weide, R., Knauf, W. U., Fiechtner, H., Kojouharoff, G., Kremers, S., & Berdel, W. E. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3065-z · Cited by 20
SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents
Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S., & Cho, H. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.002 · Cited by 20
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation
Gramegna, D., Bertoli, D., Cattaneo, C. M., Almici, C., Re, A., Belotti, A., Borlenghi, E., Lanzi, G., Archetti, S., Verardi, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04806-x · Cited by 20
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Veeraputhiran, M. K., Jain, T., Deol, A., Ayash, L. J., Kim, S., Dyson, G. E., Bhutani, D., Lum, L. G., Ratanatharathorn, V., Uberti, J. P., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.008 · Cited by 20
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Miguel, J. F. S., Gutierrez, M. A. E., Špıčka, I., Mateos, M., Song, K., Craig, M., Bladé, J., Hájek, R., Chen, C. I., Bacco, A. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185991 · Cited by 19
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias
Sridharan, A., Schinke, C., Georgiev, G. I., Ferreira, M. D. S., Thiruthuvanathan, V. J., MacArthur, I. C., Bhagat, T. D., Choudhary, G. S., Aluri, S., Chen, J., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000731 · Cited by 19
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
Sivaraj, D., Bacon, W., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Sullivan, K. M., Kang, Y., Li, Z., Chao, N. J. A., & Gasparetto, C. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.208 · Cited by 19
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F. F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220657 · Cited by 18

Research works printed but not linked: 1

Durie, 2020, Cancer J., 10, 53

Sorted by citations

Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Podocytopathies
Romagnani, P., Tang, S. C. W., Weins, A., Huber, T. B., Osafo, C., & Anders, H. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00671-w · Cited by 27
Role of Immune Cells and Immunotherapy in Multiple Myeloma
Radhakrishnan, V., Golla, U., & Kudva, A. K. (2024) · Life · doi:10.3390/life14040461 · Cited by 18
Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy
Özgencil, F., Gunindi, H. B., & Eren, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107509 · Cited by 15
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13
Self-citation

See all 19

Authors: Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Tisch Cancer Institute (US)
Corresponding author: Richter, Joshua
ORCID: Costa, Bruno Almeida
Mouhieddine, Tarek H.
Ortiz, Ricardo J.
Richter, Joshua
Venue: Critical Reviews in Oncology/Hematology
Publisher: Elsevier BV
Published: 2023-07
Volume: 187
Pages: 104040
ISSN: 1040-8428 (ISSN-L)
DOI: 10.1016/j.critrevonc.2023.104040
OpenAlex: W4378212210
Cited by: 18
References: 256
Citations by year: 2026: 3 · 2025: 8 · 2024: 6 · 2023: 1
FWCI: 0.92
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Critical Reviews in Oncology/Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords: alkylating agents, multiple myeloma, melphalan, cyclophosphamide, bendamustine, melflufen, lymphocyte depletion, CAR T-cell therapy, second primary malignancy, relapsed/refractory multiple myeloma, stem cell mobilization, pre-transplant conditioning, consolidation therapy, bridging therapy
MeSH terms: Bendamustine Hydrochloride, Receptors, Chimeric Antigen, Alkylating Agents, Cyclophosphamide, Humans, Multiple Myeloma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks